Sotagliflozin not checked

Lexicon Pharmaceuticals · SAR439954 · SAR439954/LX4211

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
4 active
16 in total · 4 in the EU
Targets
 

What this is

How it works
Makes the kidneys flush extra sugar and salt into the urine. Started as a diabetes drug; now also used for heart and kidney disease.Sodium-Glucose Cotransporter 2 Inhibitor FDA class
How it’s given
“Sotagliflozin will be administered as a tablet(s), orally once daily.”In the company’s words, NCT06481891 on ClinicalTrials.gov
Tested for
Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
Main trialPhase 3
“The main purpose of the study is to determine the changes in symptoms and functional limitations in participants with symptomatic hypertrophic cardiomyopathy (HCM) treated with sotagliflozin as compared to placebo.”In the company’s words, NCT06481891 on ClinicalTrials.gov
Other names
SAR439954 · SAR439954/LX4211

Other drugs for Non-obstructive Hypertrophic Cardiomyopathy

All 9 drugs for Non-obstructive Hypertrophic Cardiomyopathy

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials16

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Jan 2027 A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
Phase 3Completed 26 Feb 2019 Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin
Phase 3Completed 25 Mar 2019 Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control
Phase 3Completed 17 Apr 2019 Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin
Phase 3Completed 22 Apr 2019 Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy
Phase 3Completed 16 May 2019 Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
Phase 3Completed 16 May 2019 A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
Phase 3Terminated 22 May 2019 Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Phase 3Completed 6 Aug 2019 Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy
Phase 3Completed 17 Sep 2019 Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
Phase 3Terminated 5 Jun 2020 Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
Phase 3Terminated 8 Jul 2020 Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
Phase 2Terminated 17 Aug 2019 Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure
Phase 3Authorised not given Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes
Phase 2Authorised not given Sotagliflozin for the treatment of post-bariatric hypoglycaemia: The ONSIDE study
Phase 2Authorised not given Prevention of CKD progression in type 1 diabetes with Long term Use of SGLTi avoiding kidney hypOxia (PLUTO)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Sotagliflozin

Following is part of Solo: you see every change to Sotagliflozin the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in